- Insider Monkey•59 minutes agoCan Acorda Therapeutics Inc (ACOR) Give Eli Lilly And Co (LLY) A Run For Its Money In Migraine Drug Market?
Acorda Therapeutics Inc (NASDAQ:ACOR) inhaled migraine candidate CVT-427 is seen by Janney analyst Ken Trbovich as likely to give Eli Lilly and Co (NYSE:LLY) severe competition in the migraine treatment market. Eli Lilly and Co (NYSE:LLY) is acquiring CoLucid Pharmaceuticals Inc (NASDAQ:CLCD) for $960 million and that will give it access to lasmiditan, a candidate […]
- Investor's Business Daily•20 hours ago
Acorda's inhaled migraine drug could potentially rival a more "novel mechanism" from Eli Lilly.
Eli Lilly & Co. reports Q4 results the morning of January 31st. Will its expected strong earnings-per-share results be realized?
LLY : Summary for Eli Lilly and Company Common St - Yahoo Finance
Eli Lilly and Company (LLY)
NYSE - NYSE Real Time Price. Currency in USD
Add to watchlist
|Day's Range||74.17 - 76.43|
|52 Week Range||64.18 - 83.79|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||32.34|
|Dividend & Yield||2.08 (2.71%)|
|1y Target Est||N/A|